Clinton secures Aids drugs deal
Former US President Bill Clinton has agreed deals with drug companies to lower the price of Aids treatment for people in the developing world.President Bill Clinton today announced new agreements that significantly lower the price of AIDS treatment for second-line anti-retroviral drugs (ARVs), drugs required in patients who develop resistance to first-line treatment and which currently cost 10 times the price of first-line therapy. These agreements lower the prices for 16 formulations of ARVs that will generate an average savings of 25 percent in low-income countries and 50 percent in middle-income countries. Reduced prices will be available to 66 developing countries in Africa, Asia, Latin America and the Caribbean through the Clinton Foundation’s Procurement Consortium.
The deal is for so-called "second-line" Aids drugs, which are needed by patients who develop resistance to first-line treatment and currently cost ten times as much as first-line therapy.
Mr Clinton's foundation negotiated agreements with two drug makers that he said would mean "a 45 per cent saving over the price now available in Africa, and up to a 67 per cent saving in many middle income countries."
“Next Generation” HIV/AIDS Treatment Now Less Than $1 A Day
May 8, 2007
New York, NY
President Bill Clinton today announced new agreements that significantly lower the price of AIDS treatment for second-line anti-retroviral drugs (ARVs), drugs required in patients who develop resistance to first-line treatment and which currently cost 10 times the price of first-line therapy. These agreements lower the prices for 16 formulations of ARVs that will generate an average savings of 25 percent in low-income countries and 50 percent in middle-income countries. Reduced prices will be available to 66 developing countries in Africa, Asia, Latin America and the Caribbean through the Clinton Foundation’s Procurement Consortium.
Il n'y a pas qu'en Thaïlande ou au Brésil que l'on copie des médicaments. Fin mars, l'Italie a autorisé la copie à bas prix d'un médicament pour la prostate, malgré un brevet du laboratoire Merck. L'immense majorité des pays du monde se sont dotés de lois pour contourner les brevets. Dans certains cas, un gouvernement peut édicter une «licence obligatoire» forçant une entreprise à en laisser d'autres utiliser son invention, contre rémunération. Les règles internationales de l'Organisation mondiale du commerce ont entériné ce fait. Dans le cas de l'Italie, Merck a été accusé de pratiques anticoncurrentielles, et ce sont les autorités antitrust qui ont imposé cette mesure. Depuis juin 2006, cette pratique a été utilisée cinq fois aux Etats-Unis dans divers secteurs, de l'électronique à l'automobile. Dans d'autres cas, la santé publique ou la sécurité nationale sont invoquées. En 2001, les Etats-Unis ont menacé de contourner le brevet du labo Bayer sur un médicament luttant contre la maladie du charbon.
http://www.liberation.fr
Nessun commento:
Posta un commento